JP2015516421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516421A5 JP2015516421A5 JP2015511547A JP2015511547A JP2015516421A5 JP 2015516421 A5 JP2015516421 A5 JP 2015516421A5 JP 2015511547 A JP2015511547 A JP 2015511547A JP 2015511547 A JP2015511547 A JP 2015511547A JP 2015516421 A5 JP2015516421 A5 JP 2015516421A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- fasting
- auc
- meal
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 23
- 235000012054 meals Nutrition 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643486P | 2012-05-07 | 2012-05-07 | |
| US61/643,486 | 2012-05-07 | ||
| PCT/US2013/039378 WO2013169577A1 (en) | 2012-05-07 | 2013-05-03 | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516421A JP2015516421A (ja) | 2015-06-11 |
| JP2015516421A5 true JP2015516421A5 (enExample) | 2016-06-02 |
Family
ID=48428704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511547A Pending JP2015516421A (ja) | 2012-05-07 | 2013-05-03 | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150119317A1 (enExample) |
| EP (1) | EP2846778B1 (enExample) |
| JP (1) | JP2015516421A (enExample) |
| CN (1) | CN104363898A (enExample) |
| ES (1) | ES2673870T3 (enExample) |
| WO (1) | WO2013169577A1 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863331B2 (en) * | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20050249702A1 (en) * | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
| HRP20140097T1 (hr) * | 2008-11-21 | 2014-03-14 | Boehringer Ingelheim International Gmbh | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu |
| NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US20130172239A1 (en) * | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions |
| US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
-
2013
- 2013-05-03 US US14/399,114 patent/US20150119317A1/en not_active Abandoned
- 2013-05-03 CN CN201380023730.7A patent/CN104363898A/zh active Pending
- 2013-05-03 WO PCT/US2013/039378 patent/WO2013169577A1/en not_active Ceased
- 2013-05-03 ES ES13722251.9T patent/ES2673870T3/es active Active
- 2013-05-03 EP EP13722251.9A patent/EP2846778B1/en not_active Not-in-force
- 2013-05-03 JP JP2015511547A patent/JP2015516421A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2685730C1 (ru) | Составы соединений азаиндола | |
| JP2012255026A5 (enExample) | ||
| ES2725567T3 (es) | Sistema de administración transmucosa para un producto farmacéutico | |
| JP2016503030A5 (enExample) | ||
| JP2014532638A5 (enExample) | ||
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| JP2015516418A5 (enExample) | ||
| JP6276756B2 (ja) | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤 | |
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2015508068A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| CA2961528A1 (en) | Long acting pharmaceutical compositions | |
| JP2011225600A5 (enExample) | ||
| JP2016510741A5 (enExample) | ||
| RU2012127436A (ru) | Фармацевтическая композиция для местного применения, способ местного вагинального введения и способ профилактики инфицирования вич с ее помощью, презерватив ее содержащий, лекарственное средство (варианты) и способ профилактики заболеваний, передающихся половым путем | |
| JP2016510747A5 (enExample) | ||
| Kennedy et al. | Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects | |
| JP2019516765A5 (enExample) | ||
| JP2015516421A5 (enExample) | ||
| JP2015534985A5 (enExample) | ||
| EP3285764B1 (en) | Triazolopyridazines for treating cryptosporidiosis | |
| JP2016514706A5 (enExample) | ||
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| JP2015523388A5 (enExample) |